Genzyme Has Satisfying Quarter; Cerezyme Gives 'Upside Surprise'
By Randall Osborne
Friday, April 16, 2004
Genzyme Corp. reported first-quarter 2004 results that topped Wall Street's consensus, as company officials during a conference call took questions on legal challenges, patent-estate security and dosing of its enzyme-replacement therapy for Pompe disease. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.